Cargando…
Pharmacogenomics and circadian rhythms as mediators of cardiovascular drug-drug interactions
This article summarizes the current literature and documents new evidence concerning drug-drug interactions (DDI) stemming from pharmacogenomic and circadian rhythm determinants of therapies used to treat common cardiovascular diseases (CVD), such as atherosclerosis and hypertension. Patients with C...
Autores principales: | Geng, Yong-Jian, Madonna, Rosalinda, Hermida, Ramon C., Smolensky, Michael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663962/ https://www.ncbi.nlm.nih.gov/pubmed/34909660 http://dx.doi.org/10.1016/j.crphar.2021.100025 |
Ejemplares similares
-
Drug-drug interactions in polypharmacy patients: The impact of renal impairment
por: Papotti, Bianca, et al.
Publicado: (2021) -
Drug interaction and chronic obstructive respiratory disorders
por: Rogliani, Paola, et al.
Publicado: (2020) -
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders()
por: Khatri, Dharmendra Kumar, et al.
Publicado: (2021) -
Drug interactions of direct oral anticoagulants in elderly patients with cardiometabolic diseases
por: Bellia, Alfonso, et al.
Publicado: (2021) -
The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions
por: Wang, Jingya, et al.
Publicado: (2021)